Moderna, Regeneron Pharmaceuticals, AbbVie, Revolution Medicines, Gilead Sciences, Alnylam Pharmaceuticals, and Danaher are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological science to develop products such as medicines, vaccines, and diagnostic tools. For investors, they can offer substantial growth potential, but their value may be especially volatile because it often depends on clinical-trial results, regulatory approvals, and funding needs. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of NASDAQ:MRNA traded down $5.99 on Thursday, hitting $242.70. 2,349,493 shares of the company's stock were exchanged, compared to its average volume of 12,572,172. The firm's 50-day moving average is $198.57 and its 200 day moving average is $94.60. The company has a market capitalization of $98.20 billion, a PE ratio of -34.25 and a beta of 1.16. Moderna has a 1-year low of $22.28 and a 1-year high of $280.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62.
Read Our Latest Research Report on MRNA
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Shares of Regeneron Pharmaceuticals stock traded down $10.06 during trading hours on Thursday, hitting $949.35. The company had a trading volume of 360,090 shares, compared to its average volume of 833,085. The company's 50-day moving average is $811.95 and its two-hundred day moving average is $745.49. The company has a market cap of $98.21 billion, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.21 and a beta of 0.10. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89.
Read Our Latest Research Report on REGN
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded up $2.39 during mid-day trading on Thursday, reaching $297.37. 1,094,589 shares of the stock were exchanged, compared to its average volume of 6,294,656. The stock has a market capitalization of $525.63 billion, a P/E ratio of 51.17, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie has a 1 year low of $190.75 and a 1 year high of $302.93. The company has a 50 day simple moving average of $274.15 and a 200-day simple moving average of $240.18.
Read Our Latest Research Report on ABBV
Revolution Medicines (RVMD)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
NASDAQ RVMD traded down $1.78 during trading on Thursday, reaching $178.92. The company's stock had a trading volume of 1,217,003 shares, compared to its average volume of 2,804,448. Revolution Medicines has a twelve month low of $63.50 and a twelve month high of $224.31. The business's fifty day moving average price is $195.89 and its 200-day moving average price is $158.66. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36. The firm has a market cap of $38.70 billion, a price-to-earnings ratio of -19.56 and a beta of 1.44.
Read Our Latest Research Report on RVMD
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of NASDAQ:GILD traded up $0.53 during trading on Thursday, reaching $170.26. The company had a trading volume of 1,262,588 shares, compared to its average volume of 6,799,767. The firm has a market capitalization of $211.18 billion, a price-to-earnings ratio of -53.90 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The stock's fifty day moving average price is $154.40 and its 200 day moving average price is $141.51. Gilead Sciences has a fifty-two week low of $116.88 and a fifty-two week high of $176.58.
Read Our Latest Research Report on GILD
Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Shares of Alnylam Pharmaceuticals stock traded down $0.90 during trading hours on Thursday, hitting $158.95. 1,310,591 shares of the company were exchanged, compared to its average volume of 1,587,416. The company has a current ratio of 2.48, a quick ratio of 2.43 and a debt-to-equity ratio of 0.18. The business has a 50-day moving average of $223.45 and a 200-day moving average of $277.97. Alnylam Pharmaceuticals has a 1 year low of $149.18 and a 1 year high of $479.79. The stock has a market capitalization of $21.29 billion, a price-to-earnings ratio of 8.26 and a beta of 0.42.
Read Our Latest Research Report on ALNY
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
NYSE:DHR traded down $0.47 during midday trading on Thursday, reaching $234.84. The stock had a trading volume of 809,491 shares, compared to its average volume of 4,425,101. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. The stock has a market cap of $165.22 billion, a P/E ratio of 38.47, a P/E/G ratio of 2.96 and a beta of 0.76. The firm has a fifty day simple moving average of $221.67 and a two-hundred day simple moving average of $201.56. Danaher has a 12-month low of $160.93 and a 12-month high of $242.80.
Read Our Latest Research Report on DHR
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
